■抗癌药物,特别是铂类化疗药物,在接受化疗的患者中已经显示出眼部不良事件(OAE),这是令人担忧的,因为对患者的生活质量和继续有效的癌症治疗能力的潜在影响。
使用来自FDA不良事件报告系统(FAERS)数据库的铂类对OAE的自发报告进行回顾性病例/非病例研究。通过计算比例报告比率(PRR)进行不相称性分析,报告赔率比(ROR),和信息组件(IC)来识别基于铂的化疗药物的OAE信号。并行,通过在PubMed和GoogleScholar中进行系统的文献检索,对来自铂类的OAE病例报告进行了综述.
■使用不成比例分析,针对基于铂的化疗药物和OAE鉴定了69个信号(卡铂:42,奥沙利铂:16,顺铂:11)。脉络膜梗死[PRR=215.1;χ2=4527.1;下限(LB)ROR=140.7;IC025=5.1]和眼眶出血[PRR=120.0;χ2=300.5;LBROR=35.1;IC025=1.3]是卡铂的强信号。视盘充血[PRR=208.2;χ2=742.5;LBROR=74.1;IC025=2.2]和皮质盲[PRR=23.7;χ2=382.5;LBROR=14.8;IC025=3.1]是奥沙利铂和顺铂的信号,分别。通过在PubMed和GoogleScholar的系统搜索,共发现了32例铂类化疗药物的OAE病例报告,加强协会。
■该研究揭示了使用铂类化疗药物作为抗癌药物时OAE的潜在风险。
该研究旨在调查与铂类化疗药物相关的眼部不良事件(OAE)的风险,即顺铂,卡铂,和奥沙利铂.分析来自药物警戒数据库的数据,并对病例报告进行系统审查,以识别和理解这些潜在风险。他们的药物警戒分析显示,许多报告详述了与这些铂类药物相关的OAE。值得注意的发现包括表明严重不良事件的信号,如失明,视网膜毒性,和视神经损伤.进一步完善这些信号,考虑到并发药物的影响,证实了铂类药物和OAE之间的关联。此外,病例报告的系统综述提供了在接受铂类化疗的患者中观察到的特定OAE的见解.常见的不良事件包括视力损害,视网膜问题,和隧道视觉,一些患者正在经历不可逆的视力丧失。该研究强调了在铂类化疗患者中识别和监测OAE的重要性。它强调医疗保健提供者需要在治疗前仔细评估患者的眼部病史,并且监管机构需要将相关发现纳入药物安全指南。总的来说,该研究通过提供与铂类化疗药物相关的眼部毒性的全面信息,增强了患者护理和癌症治疗的安全性.
UNASSIGNED: Anti-cancer drugs, particularly platinum-based chemotherapy drugs, have been showing ocular adverse events (OAEs) in patients undergoing chemotherapy, which is concerning due to the potential impact on patient\'s quality of life and the ability to continue effective cancer treatment.
UNASSIGNED: A retrospective case/non-case study was conducted using spontaneous reports on OAEs by platins from the FDA Adverse Event Reporting System (FAERS) database. A disproportionality analysis was performed by calculating the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and the Information Component (IC) to identify OAE signals for platinum-based chemotherapy drugs. In parallel, a
review of case reports for OAEs from platins was conducted by a systematic literature search in PubMed and Google Scholar.
UNASSIGNED: Using disproportionality analysis, 69 signals were identified for platinum-based chemotherapy drugs and OAEs (carboplatin: 42, oxaliplatin: 16, cisplatin: 11). Choroidal infarction [PRR = 215.1; χ2 = 4527.1; lower bound (LB) ROR = 140.7; IC025 = 5.1] and orbital hemorrhage [PRR = 120.0; χ2 = 300.5; LB ROR = 35.1; IC025 = 1.3] were the strong signals identified for carboplatin. Optic disc hyperemia [PRR = 208.2; χ2 = 742.5; LB ROR = 74.1; IC025 = 2.2] and blindness cortical [PRR = 23.7; χ2 = 382.5; LB ROR = 14.8; IC025 = 3.1] were the signals identified for oxaliplatin and cisplatin, respectively. A total of 32 case reports of OAEs from platinum-based chemotherapy drugs were identified through a systematic search in PubMed and Google Scholar, strengthening the association.
UNASSIGNED: The study revealed a potential risk of OAEs when using platinum-based chemotherapy drugs as an anticancer medication.
The study aimed to investigate the risk of ocular adverse events (OAEs) associated with platinum-based chemotherapy drugs, namely cisplatin, carboplatin, and oxaliplatin. Analyzed data from pharmacovigilance databases and conducted a systematic
review of case reports to identify and understand these potential risks.The Pharmacovigilance analysis revealed many reports detailing OAEs related to these platinum-based drugs. Notable findings included signals indicating serious adverse events such as blindness, retinal toxicity, and optic nerve damage. Further refinement of these signals, considering the influence of concurrent medications, confirmed the association between platinum drugs and OAEs.Additionally, the systematic
review of case reports provided insights into specific OAEs observed in patients receiving platinum-based chemotherapy. Common adverse events included vision impairment, retinal issues, and tunnel vision, with some patients experiencing irreversible vision loss.The study highlighted the importance of recognizing and monitoring OAEs in platinum-based chemotherapy patients. It emphasized the need for healthcare providers to assess patients’ ocular histories carefully before treatment and for regulatory authorities to incorporate relevant findings into drug safety guidelines. Overall, the research enhances patient care and safety in cancer treatment by providing comprehensive information on the ocular toxicity associated with platinum-based chemotherapy drugs.